Inpharma

Statins poor contenders for OTC status, says expert
pp. 2-2(1)

Sialidase inhibitors: the future of flu treatment?
pp. 2-2(1)

Drivers of antibacterial resistance key to better control
pp. 2-2(1)

Immunotherapy with BCG vaccine warranted in colorectal cancer
pp. 3-3(1)

Paediatric bipolar disorder guidelines issued, discussed
pp. 3-3(1)

Don't stress: UK NICE issues PTSD guidelines
pp. 3-3(1)

Long-term clopidogrel a cost-effective CURE in ACS
pp. 4-4(1)

Rise in use of antiasthmatics behind a fall in paediatric asthma rate?
pp. 4-4(1)

Imatinib cost effective vs bone marrow transplantation in CML
pp. 4-4(1)

Routine pneumococcal vaccination reasonably cost effective in Spain
pp. 5-5(1)

Rimonabant pulls its weight in treating obesity
pp. 5-5(1)

The symptoms of rheumatoid arthritis may be improved by treatment with belimumab,
pp. 5-5(1)

R&D news from the 54th Annual Scientific Session of the ACC
pp. 6-7(2)

ALLHAT's off to thiazide diuretics in Blacks with hypertension
pp. 8-8(1)

XP 13512 may reduce the pain associated with postherpetic neuralgia
pp. 8-8(1)

The oral fumarate BG 12 may reduce the symptoms of psoriasis
pp. 8-8(1)

Mycophenolate mofetil (MMF) reduces the incidence of early rejection episodes and improves survival in paediatric heart transplant recipients
pp. 8-8(1)

Sirolimus-eluting stent superior: the REALITY hits home
pp. 10-10(1)

Paclitaxel-eluting stent rises to the challenge in high-risk patients
pp. 11-11(1)

Topiramate is effective in patients with essential tremor refractory to previous treatment
pp. 11-11(1)

Long-term treatment with rivastigmine appears to be beneficial in patients with dementia associated with Parkinson's disease
pp. 11-11(1)

Aripiprazole is effective in patients with Gilles de la Tourette's syndrome
pp. 11-11(1)

Parathyroid hormone in tip-TOP shape for osteoporosis
pp. 11-11(1)

Azithromycin produces long lasting control of C. trachomatis infection
pp. 12-12(1)

Clopidogrel can carry a heavy load
pp. 12-12(1)

Shocking reduction with amiodarone in ICD recipients
pp. 12-12(1)

Buflomedil reduces the risk of complications and improves claudication in patients with peripheral arterial occlusive disorders
pp. 12-12(1)

Amlodipine + perindopril rival standard therapy for hypertension
pp. 13-14(2)

Ezetimibe added to rosuvastatin produces further reductions in LDL-cholesterol levels in patients with severe hypercholesterolaemia
pp. 14-14(1)

Naltrexone reduces heavy drinking in alcohol dependence
pp. 15-15(1)

Pre-emptive strike on BK by reducing immunosuppression
pp. 15-15(1)

Fluoroquinolones demonstrate in vitro activity against multi-drug resistant Streptococcus pneumoniae (MDRSP)
pp. 15-15(1)

Rituximab improves symptoms in patients with rheumatoid arthritis
pp. 15-15(1)

Atorvastatin has rapid and early anti-inflammatory effects in patients with acute coronary syndrome
pp. 16-16(1)

Is it bye-bye Bextra in the US, EU and Canada?
pp. 16-16(1)

The risk of tardive dyskinesia appears to be lower for olanzapine (2.5-20mg) than for conventional antipsychotics
pp. 17-17(1)

Aripiprazole may be associated with dyskinesias
pp. 17-17(1)

US product approvals
pp. 17-17(1)

Antipsychotics are not the only drugs associated with movement disorders
pp. 17-17(1)

Rasagiline appears to be relatively well tolerated, find two 6-month, randomised, placebo-controlled trials
pp. 17-17(1)

Other US regulatory news
pp. 18-18(1)

Product launches in Japan
pp. 18-18(1)

Product approvals in Japan
pp. 18-18(1)

US product launches
pp. 18-18(1)

Health Canada has approved letrozole [Femara; Novartis] for the extended adjuvant treatment of hormone receptor-positive early breast cancer
pp. 18-18(1)

Product Introductions
pp. 19-19(1)